These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 31367906)

  • 41. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
    Ganem J; Thureau S; Gouel P; Dubray B; Salaun M; Texte E; Vera P
    PLoS One; 2019; 14(10):e0222885. PubMed ID: 31603916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.
    Seki S; Fujisawa Y; Yui M; Kishida Y; Koyama H; Ohyu S; Sugihara N; Yoshikawa T; Ohno Y
    Magn Reson Med Sci; 2020 Feb; 19(1):29-39. PubMed ID: 30880291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT.
    Brown PJ; Zhong J; Frood R; Currie S; Gilbert A; Appelt AL; Sebag-Montefiore D; Scarsbrook A
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2790-2799. PubMed ID: 31482428
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
    PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
    Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data.
    Gregory DL; Hicks RJ; Hogg A; Binns DS; Shum PL; Milner A; Link E; Ball DL; Mac Manus MP
    J Nucl Med; 2012 Jul; 53(7):1007-15. PubMed ID: 22677701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer.
    Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L
    Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118
    [No Abstract]   [Full Text] [Related]  

  • 50. Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy.
    Grootjans W; Usmanij EA; Oyen WJ; van der Heijden EH; Visser EP; Visvikis D; Hatt M; Bussink J; de Geus-Oei LF
    Radiother Oncol; 2016 Jun; 119(3):473-9. PubMed ID: 27178141
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of preoperative [
    Lin JT; Li XM; Zhong WZ; Hou QY; Liu CL; Yu XY; Ye KY; Cheng YL; Du JY; Sun YQ; Zhang FG; Yan HH; Liao RQ; Dong S; Jiang BY; Liu SY; Wu YL; Yang XN
    Ann Nucl Med; 2024 Mar; 38(3):188-198. PubMed ID: 38145431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is post-treatment standardized uptake value a prognostic factor in unresectable non-small cell lung carcinoma?
    Yılmaz U; Yasar Z; Korkmaz E; Yalcın B; Koparal H; Ozbilek E
    Med Glas (Zenica); 2017 Aug; 14(2):204-210. PubMed ID: 28698535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary tumor standardized uptake value (SUVmax) measured on
    Hui Z; Wei F; Ren H; Xu W; Ren X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
    Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Ohri N; Bodner WR; Halmos B; Cheng H; Perez-Soler R; Keller SM; Kalnicki S; Garg M
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):372-380. PubMed ID: 28068244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
    Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
    Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
    Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
    Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Horne ZD; Clump DA; Vargo JA; Shah S; Beriwal S; Burton SA; Quinn AE; Schuchert MJ; Landreneau RJ; Christie NA; Luketich JD; Heron DE
    Radiat Oncol; 2014 Jan; 9():41. PubMed ID: 24479954
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.
    Brose A; Michalski K; Ruf J; Tosch M; Eschmann SM; Schreckenberger M; König J; Nestle U; Miederer M
    Cancer Imaging; 2023 May; 23(1):45. PubMed ID: 37198668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
    Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
    Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.